Transcription of Alnylam Forward Looking Statements
{{id}} {{{paragraph}}}
1 2022 Alnylam Pharmaceuticals, 2022 Alnylam PharmaceuticalsNathan (USA)Diagnosed with AHP2 Alnylam Forward Looking StatementsThispresentationcontainsforwar d-lookingstatementswithinthemeaningofSec tion27 AoftheSecuritiesActof1933andSection21 EoftheSecuritiesExchangeActof1934,includ ingexpectationsregardingouraspirationtob ecomealeadingbiotechcompanyandtheplanned achievementofour AlnylamP5x25 strategy,ourabilitytoattainfinancialself -sustainability,ourpreliminaryfourthquar terand2021fiscalyearglobalnetproductreve nueandpatientsontherapy,theprobabilityof successofourRNAitherapeuticsplatform.
Notable Accomplishments in 2021 * Preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results in February 2022. 2 NDA/sNDA submissions (vutrisiran, OXLUMO®) Completed enrollment in two key Phase 3 studies in ATTR-CM
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}